Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2023 | $9.00 | Overweight | Stephens |
| 7/19/2023 | Mkt Perform | Raymond James | |
| 2/15/2022 | $27.00 → $18.00 | Equal-Weight | Morgan Stanley |
| 1/6/2022 | $20.00 | Overweight | Piper Sandler |
| 10/15/2021 | Outperform | Cowen | |
| 8/17/2021 | Outperform | Cowen | |
| 8/17/2021 | Equal-Weight | Morgan Stanley | |
| 8/17/2021 | $26.00 | Equal-Weight | Morgan Stanley |
FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024. Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek's 2023 revenue of $193.0 million. This included a negative foreign exchange impact of approximately $1.0 million. Expected fourth quarter revenue of $57 million to $58 million represents growth of 11% to 13% compared to the third quarter of 2024 and decline of 2% to flat compared to a strong fourth quarter of 2023. The appreciation of the
FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Cytek management is scheduled to present on Thursday, January 16th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysi
FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024. The new repurchase program is authorized to commence on January 1, 2025 and remain in effect until December 31, 2025 unless extended or shortened by the Board of Directors. Any repurchases under the 2025 repurchase program will be made in the open market and/or in private
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-
FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force. "Philippe's extensive global sales and marketing experience as an executive at several life science companies, incl
8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00
Raymond James initiated coverage of Cytek Biosciences with a rating of Mkt Perform
Morgan Stanley reiterated coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $18.00 from $27.00 previously
SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
FREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Total revenue for the third quarter of 2024 was $51.5 million, representing a 7% increase over the third quarter of 2023 and a 10% increase over the second quarter of 2024. Year-to-date revenue of $143.0 million at September 30, 2024 was 6% above the same 9 month period in 2023 Launched SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes, expanding the capabilities of the Pane
FREMONT, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 5, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the nex
FREMONT, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Total revenue for the second quarter of 2024 was $46.6 million, representing a 4% increase sequentially over the first quarter of 2024 and a 6% decrease over the second quarter of 2023For the first half of 2024, total revenue grew 5% compared to the first half of 2023Launched Enhanced Small Particle (ESP™) detection, an upgrade option for the Cytek Aurora™ and Northern Lights™ systems for the analysis of viruses and other sub-